常见产品
Common Products
相关产品
「同位素标记抑制剂」Lapatinib-d7 dihydrochloride
- 产品货号:E-T202508210001
- 发布时间:2025-08-21
- 产品CAS :N/A
- 产品规格:mg
- 产品纯度:≥95%
- 产品货期:现货下单后48小时内发货,定制产品4-8周。
- 运输条件:顺丰常规运输
产品详情
货号:E-T202508210001
CAS:N/A
规格:mg
纯度:≥95%
生产商:试剂家
生物活性:Lapatinib-d7 (dihydrochloride) is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Lapatinib-d7 dihydrochloride 相关抗体:
c-Fos Antibody
Caveolin-1 Antibody
Ferritin Heavy Chain Antibody
Phospho-EGFR (Tyr1068) Antibody
Phospho-EGFR (Tyr1173) Antibody
c-Fos Antibody (YA506)
EGF Antibody
EGFR Antibody
EGR1 Antibody
Phospholipase C gamma 1 Antibody
Phospho-EGFR (Tyr1068) Antibody (YA204)
HER2 Antibody
EGFR Antibody (YA775)
HER2 Antibody (YA771)
ErbB 4 Antibody
AMID/FSP1 Antibody
Peroxiredoxin 1 Antibody (YA692)
Phospho-EGFR (Tyr1092) Antibody
TGF alpha Antibody
PRDX3 Antibody (YA909)
HBEGF Antibody (YA1801)
ErbB 3 Antibody
Ferritin Light Chain Antibody (YA971)
Ferritin Light Chain Antibody (YA972)
GRB7 Antibody (YA1165)
分子量:661.02
Formula:C29H21D7Cl3FN4O4S
非标记 CAS:231277-92-2
中文名称:拉帕替尼 d7 (双盐酸盐)
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (534 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]
[2]. Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94
[Content Brief]
在线留言
欢迎您访问“试剂家 | 纳米靶向科研平台”官方网站,请留下您的需求,我们会派专业人员及时与您联系,并为您提供相应的产品方案。